After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way last month. | After spending much of the year sloping steadily downward from ...
Like any medication, Dupixent may cause various side effects. It’s especially known to cause side effects relating to the eyes, such as conjunctivitis, blepharitis, and keratitis. These side effects ...
On November 11, 2025, Sanofi and Regeneron announced that the FDA accepted for priority review its supplemental biologics license application ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...
Recently, the U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent in adults and children aged 6 years and older with ...
The first time I heard “ Situation ” by Yaz, a British synth-pop duo, I was in a lesbian club filled with mostly closeted ...
Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...
LONDON, Oct 24 (Reuters) - Sanofi (SASY.PA), opens new tab reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent, even as the French ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...